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INTRODUCTION
Fibrosis of tumors contributes to invasion and progression 
thereof.1 As a tumor grows, intratumoral hypoxia is induced, 
and the hypoxia-inducible factor (HIF)-1α pathway is activat-
ed. Concomitantly, abnormally activated tumor fibroblasts 
activate vascular endothelial growth factor (VEGF), which in-
duces (lymph)angiogenesis.2 Hypoxia also induces Wnt/beta-
catenin signaling. Studies have demonstrated that activated 
beta-catenin is associated with metastatic potential and poor 
prognosis in several cancers.3,4 In breast cancer, tumor fibrosis 
has been shown as a surrogate marker for hypoxia and (lymph)
angiogenesis.5,6 Fibrotic tumor stroma induces angiogenesis 
by promoting the expression of hypoxia-related genes, result-
ing in tumor progression and metastasis via lymphovascular 
invasion.7,8
Screening breast ultrasound (US) plays an important role in 
detection of early breast cancer.9 Recently, shear-wave elastog-
raphy (SWE) has been used to evaluate breast mass stiffness 
during routine US examination since the method helps to dif-
ferentiate benign from malignant masses.10,11 As the elasticity 
value reflects the hardness of an object and has been found to 
correlate with fibrosis, SWE is also used to screen for prostate 
cancer12,13 and evaluate for liver fibrosis in patients with hepa-
titis and primary biliary cirrhosis.14 Moreover, as SWE takes 
great advantage of quantitative estimation, statistical analyses 
of the correlation between various histologic parameters and 
tumor stiffness are possible. Studies investigating the associa-
tion between a higher elasticity value and higher rate of predic-
tion of cancer diagnosis have been reported.15-17 In this study, 
we aimed to correlate lymphangiogenesis with the stiffness of 
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breast cancers and to analyze the value of predicting lymph 
node metastasis and other clinicopathologic parameters. 
MATERIALS AND METHODS
Patients and clinicopathologic data
This study has been approved by the Institutional Review Board 
of Severance Hospital (IRB No. 4-2015-0113). Between July 
2012 and March 2013, 639 breast masses were imaged by gray-
scale US and SWE. Core needle biopsy demonstrated breast 
cancer in 150 patients, who subsequently underwent mastec-
tomy with axillary lymph node dissection. After excluding 10 
patients who had received neoadjuvant chemotherapy, data 
from 140 patients were analyzed in this study. Pathology reports 
of the preoperative biopsy and mastectomy specimens were 
reviewed and hematoxylin and eosin slides of resected speci-
men were reviewed to determine the histologic type, invasive 
size, extensive intraductal component (EIC, defined as occu-
pying 25% or more of the tumor area), histologic grade, lym-
phovascular invasion, and axillary lymph node metastasis.
SWE examinations
Breast US examinations were performed using the Aixplorer US 
system (SuperSonic Imagine, Aix-en-Provence, France), which 
was equipped with a 4–15-MHz linear-array transducer, by one 
of four radiologists with 5–10 years of experience in breast US 
exams. The investigators were aware of the clinical examination 
and mammography results at the time of examination. After 
obtaining gray-scale US, SWE images were obtained for breast 
masses that were scheduled for biopsy or surgical excision. The 
built-in region-of-interest (ROI) (Q-box; SuperSonic Imagine) 
of the system was set to include the lesion and surrounding nor-
mal tissue, which was displayed as a gray-scale image overlaid 
with a semitransparent color map of tissue stiffness, ranging 
from dark blue, which indicated the lowest stiffness, to red, 
which indicated the highest stiffness (0–180 kPa). Areas of black 
on the SWE images represented tissue in which no shear wave 
Fig. 1. Lymphangiogenesis in fibrous stroma in tumor with high elasticity value and low elasticity value. In tumor with high elasticity value (case 19, 
mean elasticity value: 230.0 kPa) shows lymphatic spaces (maximal microlymphatic density: 23.0) embedded in fibrotic tumor stroma (A), which are 
highlighted by D2-40 immunohistochemical staining (B). In tumor with low elasticity value (case 116, mean elasticity value: 56.5 kPa), lymphatic space 
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was detected. Fixed 2×2-mm ROIs were placed by an investi-
gator over the stiffest part of the lesion, including immediate 
adjacent stiff tissue or halo. The system calculated the mean 
elasticity values in kPa for the mass.
Interpretation of immunohistochemistry and HER2 
fluorescence in situ hybridization evaluation 
For the immunohistochemical evaluation of ER, PR, HER2, and 
Ki-67 labeling index (LI) status, formalin-fixed, paraffin-em-
bedded (FFPE) tissue sections obtained from the surgical spec-
imens were stained with appropriate antibodies for ER (clone 
6F11; 1:200; Novocastra, Newcastle upon Tyne, UK), PR (clone 
16; 1:200; Novocastra), Ki-67 (clone MIB-1; 1:1000; Dako, Glos-
trup, Denmark), HER2 (clone 4B5; prediluted; Roche diagnos-
tics). A cut-off value of ≥1% positively stained nuclei was used 
to define ER and PR positivity.9 HER2 staining was analyzed 
according to the American Society of Clinical Oncology/College 
of American Pathologists guidelines, using the following cate-
gories: 0=no immunostaining; 1+=weak incomplete membra-
nous staining in <10% of the tumor cells; 2+=complete mem-
branous staining, either uniform or weak, in ≥10% of the tumor 
cells; and 3+=uniform intense membranous staining in ≥30% 
of the tumor cells.18 HER2 immunostaining was considered 
positive when strong (3+) membranous staining was observed, 
whereas 0 or 1+ cases were considered negative. Tumors with 
a score of 2+ were sent for fluorescence in situ hybridization 
(FISH) testing performed using the PathVysion HER2 DNA 
Probe Kit (Abbott-Vysis, Des Plaines, IL, USA). This test deter-
mines the HER2 amplification in the event the ratio of the HER2 
gene signal to chromosome 17 signal is more than 2, which is 
classified as positive.
Based on immunohistochemistry or FISH results of ER, PR, 
Table 1. Results from Univariate Regression Analysis of Clinicopathological Variables and the Mean Elasticity Value
Variable Number (total=140) Mean elasticity value (kPa) β coefficient p value
Age -0.122±0.376 0.745
Size of invasive tumor 12.49±3.84 0.001
Maximal microlymphatic density 1.106±0.496 0.027
Histologic type
Ductal 111 142.52±52.26 6.84±11.98 0.569
Lobular 7 151.74±39.17 16.07±22.28 0.472
Specified 22 135.68±49.47 0
Molecular type
Luminal A 64 135.89±40.12 0
Luminal B 18 151.57±70.60 15.67±13.68 0.254
HER2 32 143.56±56.02 7.66±11.10 0.491
TNBC 26 147.97±54.48 12.07±11.93 0.313
Histologic grade
1 29 122.25±48.80 0
2 78 140.56±51.95 18.31±10.80 0.092
3 33 162.35±44.38 40.10±12.63 0.002
Extensive intraductal component 38 126.14±47.70 -21.45±9.57 0.027
Axillary lymph node metastasis 40 165.23±57.47 32.65±9.18 0.001
Lymphovascular invasion 18 161.94±62.23 22.99±12.79 0.075
ER
Negative 42 147.82±55.52 0
Positive 98 139.37±49.13 -8.45±9.43 0.371
PR
Negative 60 146.53±54.76 0
Positive 80 138.43±48.19 -8.10±8.73 0.355
HER2
Negative 108 141.41±49.79 0
Positive 32 143.56±56.02 2.14±10.62 0.836
p53
Negative 72 139.50±49.72 0
Positive 68 144.44±52.73 4.94±8.66 0.569
Ki-67 labeling index 0.857±0.28 0.003
TNBC, triple-negative breast cancer.
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HER2, and Ki-67 LI status, the tumors were divided into four 
subtypes: luminal A (ER-positive and/or PR-positive, HER2-
negative, and Ki-67 LI<14%); luminal B (ER-positive and/or 
PR-positive, HER2-negative, and Ki-67 LI ≥14% or ER-positive 
and/or PR-positive and HER2-positive, irrespective of Ki-67 LI); 
HER2-enriched (ER-negative, PR-negative, and HER2-posi-
tive); and triple-negative breast cancer (TNBC) (ER-negative, 
PR-negative, and HER2-negative).
Microlymphatic density 
To evaluate lymphangiogenesis, available 134 FFPE tissue sec-
tions obtained from the surgical specimens were stained with 
antibodies against D2-40 (1:100; Dako). Immunohistochemical 
staining for D2-40 was performed on the most fibrotic area aro-
und the tumor (Fig. 1). Each stained slide was examined at 100× 
magnification and counted for lymphatic spaces. Completely 
D2-40 surrounded spaces without containing red blood cells 
were counted. 
Statistical analysis 
The mean elasticity value (calculated using SWE) and micro-
lymphatic density were correlated with clinicopathologic pa-
rameters using univariate and multivariate regression models. 
Data were analyzed using the statistical software SPSS (version 
20, SPSS Inc., Chicago, IL, USA). Differences with p<0.05 were 
considered statistically significant.
RESULTS
The mean age of the 140 patients included in this study was 
52.7 years (range 28–81 years). The mean elasticity value was 
Table 2. Results from Univariate Regression Analysis of Clinicopathological Variables for Lymphangiogenesis in Breast Cancer
Variable Number (total=134) Maximal microlymphatic density β coefficient p value
Age -0.09±0.07 0.154
Size of invasive area 0.78±0.69 0.258
Mean elasticity value 0.033±0.015 0.027
Histologic type
Ductal 107 13.93±9.05 1.49±2.14 0.490
Lobular 7 9.43±6.24 -3.02±3.86 0.435
Specified 20 12.45±7.98 0
Molecular type
Luminal A 61 12.21±6.49 0
Luminal B 18 13.94±12.30 1.73±2.36 0.465
HER2 30 14.67±9.09 2.45±1.97 0.214
TNBC 25 14.80±10.41 2.59±2.09 0.219
Histologic grade
1 26 11.62±6.55 0
2 76 12.95±9.35 1.33±1.98 0.502
3 32 16.25±8.61 4.64±2.30 0.046
Extensive intraductal component 38 14.74±9.74 1.76±1.69 0.299
Axillary lymph node metastasis 39 15.03±10.18 2.18±1.67 0.193
Lymphovascular invasion 18 16.78±12.93 3.81±2.21 0.087
ER
Negative 41 15.22±10.14 0
Positive 93 12.71±8.07 -2.51±1.64 0.128
PR
Negative 59 14.10±9.15 0
Positive 75 12.99±8.54 -1.12±1.53 0.468
HER2
Negative 104 13.13±8.72 0
Positive 30 14.67±9.09 1.53±1.83 0.403
p53
Negative 68 12.15±7.44 0
Positive 66 14.85±9.87 2.70±1.51 0.075
Ki-67 labeling index 0.11±0.05 0.030
TNBC, triple-negative breast cancer.
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141.90 kPa (range 16.10–294.30 kPa). The mean of maximal 
number of lymphatic spaces was 13.48 (range 1–53). The histo-
logical cancer types were as follows: invasive ductal carcinoma 
(n=111, 79.3%), invasive lobular carcinoma (n=7, 5.0%), and 
others (n=22, 15.7%; four medullary, four tubular, three muci-
nous, two micropapillary, two papillary, two pleomorphic, two 
cribriform, one apocrine, one metaplastic, and one solid pap-
illary). Based on immunohistochemistry or FISH results of ER, 
PR, HER2, and Ki-67 LI status, the molecular cancer types were 
as follows: luminal A (n=64, 45.7%), luminal B (n=18, 12.9%), 
HER2 (n=32, 22.9%), and TNBC (n=26, 18.6%).
By univariate regression analysis, mean elasticity value was 
positively correlated with the invasive tumor size, histologic 
grade 3, Ki-67 LI, axillary lymph node metastasis, and micro-
lymphatic density, and negatively correlated with EIC (Table 1). 
No significant differences were found among histologic or mo-
lecular types of tumor. Lymphovascular invasion showed ten-
dency of correlation with the mean elasticity value. Microlym-
phatic density was associated significantly with mean elasticity 
value, histologic grade 3, and Ki-67 LI (Table 2). By multivariate 
regression analysis, axillary lymph node metastasis (p=0.03) 
and Ki-67 LI (p=0.045) were significantly correlated with mean 
elasticity value (Table 3). In terms of lymphangiogenesis, signif-
icant correlation was observed between mean elasticity value 
and maximal microlymphatic density (p=0.044) (Table 4). How-
ever, histologic grade, axillary lymph node metastasis, EIC, 
and Ki-67 LI did not correlate with maximal microlymphatic 
density. 
DISCUSSION
In this study, we aimed to correlate tumor stiffness, measured 
by SWE, with clinicopathologic parameters and lymphangio-
genesis of breast cancer. As shown in the previous studies, large 
invasive size, axillary lymph node involvement, higher histo-
logic grade, increased proliferative index, lymphovascular in-
vasion were significantly correlated with higher elasticity val-
ue.10,11,19,20 However, the EIC showed a negative correlation with 
the mean elasticity value in our study. This might be due to the 
lack of a desmoplastic reaction in intraductal component, in 
contrast to the invasive tumor which induces desmoplastic fi-
brosis and higher elasticity value. Also, there was no significant 
correlation between histologic and molecular subtypes with 
tumor thickness. According to Chang, et al.,10 tumor elasticity 
varied significantly based on histologic subtypes. Contrasting-
ly, Youk, et al.19 reported no significant correlation between tu-
mor elasticity and histologic and molecular subtypes. These 
contradictory results indicate the requirement for further pre-
cise investigation into whether histologic and molecular sub-
types correlate with tumor stiffness. 
Multivariate regression analysis demonstrated that axillary 
lymph node metastasis was independently associated with 
high elasticity value, which was consistent with an earlier study 
that reported high elasticity value as an independent predictive 
factor of axillary lymph node metastasis.21 Also, studies have 
also shown that a higher histologic grade, large invasive size, 
and histologic subtypes of TNBC and HER2 types correlate in-
dependently with a higher elasticity value.10,11,19 However, in 
this study, only axillary lymph node metastasis was indepen-
dently correlated with high elasticity value, which may be at-
tributed to our relatively small sample size. In a prior study, 
Youk, et al.19 showed that Ki-67 LI in tumor cells correlated 
with higher elasticity value in univariate regression analysis, 
while multivariate analysis showed only a tendency towards 
correlation. However, our data showed a significant association 
between Ki-67 LI and elasticity value. This discordance might 
originate from different methods of data analysis used in the 
two studies: we analyzed Ki-67 LI as a continuous variable, 
whereas Youk, et al.19 divided patients into two groups accord-
ing to Ki-67 LI, namely Ki-67>14% and Ki-67≤14%.
Lymphangiogenesis was found to be strongly associated with 
higher elasticity value, histologic grade, and Ki-67 LI in uni-
variate regression analysis. Higher histologic grade and Ki-67 
LI are frequently observed in malignant tumors, which are as-
sociated with poor prognosis,22 which exhibit rapid progression, 
frequent metastasis, and (lymph)angiogenesis.23,24 However, 
axillary lymph node metastasis was not found to be correlated 
with lymphangiogenesis in univariate and multivariate regres-
sion analyses in present study. Only the mean elasticity value 
was independently correlated with lymphangiogenesis. This 
result suggests that tumor stiffness is important for develop-
ing new lymphatic spaces, which is consistent with prior stud-
ies in the literature demonstrating an association between tu-
mor fibroblast and hypoxia with (lymph)angiogenesis.5,25 Apart 
from metastasis, Lee, et al.18 reported that breast cancer patients 
having multiple primary cancers show poor prognosis, although 
the breast cancer was at an early stage. It would be worthy to 
analyze the elasticity value of patients with multiple primary 
cancers and correlate the elasticity value and clinicopatholog-
ic characteristics of those patients.
Table 3. Results from Multivariate Regression Analysis of Clinicopatho-
logic Variables and the Mean Elasticity Value
Variable β coefficient p value
Ki-67 labeling index 0.57±0.28 0.045
Axillary lymph node metastasis 28.0±9.16 0.003
Maximal microlymphatic density 0.84±0.48 0.085
Extensive intraductal component -16.15±9.31 0.085
Table 4. Results from Multivariate Regression Analysis of Clinicopatho-
logic Variables for Lymphangiogenesis in Breast Cancer
Variable β coefficient p value
Mean elasticity value 0.03±0.02 0.044
Ki-67 labeling index 0.10±0.05 0.058
Extensive intraductal component 2.91±1.68 0.085
http://dx.doi.org/10.3349/ymj.2016.57.3.599604
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Fibrosis observed in the center and periphery of tumors cor-
relates well with elasticity value. In malignant tumors, the extra-
cellular matrix (ECM) induces abnormal crosslinking of colla-
gen, which could explain the higher elasticity value observed 
in malignant tumors. ECM-induced activation of the phos-
phoinositide 3-kinase pathway is thought to play an important 
role in tumor cell invasion.24 Fibrotic foci in cancer have also 
been shown to be associated with poor prognosis, as well as 
lymphangiogenesis and angiogenesis.1,5,26
Unlike normal fibroblasts in the wound healing process, tu-
mor fibroblasts are continuously activated. VEGF is critical in 
the development of this reactive stroma in tumors. Additionally, 
intratumoral hypoxia induces activation of the HIF-1α pathway, 
and VEGF induces angiogenesis.7 More angiogenesis is induced 
as the fibrotic area of the tumor expands, which could be the 
result of interaction between the tumor stroma and intratu-
moral hypoxia.25 In addition, expression of carbonic anhydrase 
IX, a hypoxia marker, has been found to be associated with tu-
mor fibrosis.27 In previous studies, HIF-1α and VEGF induce 
lymphangiogenesis and angiogenesis, that these two hypoxia-
related molecules are thought to be linked to tumor aggressive-
ness and poor prognosis.6,28
In this study, we confirmed that mean elasticity value cor-
related significantly with poor prognostic factors. Additionally, 
we found that tumor stiffness was independently correlated 
with lymphangiogenesis. Our data also suggest that tumor stiff-
ness measured by SWE may be related to hypoxia-related gene 
expression and activation of cancer fibroblasts, which could 
be potential targets by therapeutic strategies for treating can-
cer. In conclusion, lymphangiogenesis in breast cancer corre-
lated significantly with the mean elasticity value, which re-
flects tumor stiffness and poor prognosis.
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